PMID- 34868320
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211207
IS  - 1687-966X (Print)
IS  - 1687-9678 (Electronic)
VI  - 2021
DP  - 2021
TI  - Dual Effects of Hypoxia-Inducible Factors-1 Alpha in Bleomycin-Induced Pulmonary 
      Fibrosis Treated by Human Umbilical Cord Mesenchymal Stem Cells.
PG  - 6658855
LID - 10.1155/2021/6658855 [doi]
LID - 6658855
AB  - Pulmonary fibrosis (PF) is a kind of lung disease characterized by scar formation 
      and inflammation damage. Mesenchymal stem cells (MSCs) are considered a promising 
      therapy because of multidirectional differentiation and immune regulation. Our 
      research was designed for identifying the preventative defensive ability and 
      therapeutic effect of human umbilical cord mesenchymal stem cells (HUCMSCs). 
      HUCMSCs were administered before or after bleomycin injection in different groups 
      of C57BL/6 mice. We calculated the survival time of mice, the lung coefficients, 
      contents of hydroxyproline, and pathological scores. The expression levels of 
      HIF-1alpha (hypoxia-inducible factor-1alpha), alpha-SMA (alpha-smooth muscle actin), gammaH(2)AFX 
      (gammaH2A histone family, member X), ZO-1 (zonula occludens-1), ROS (reactive oxygen 
      species) content, and proliferation ability of A549 cells were detected after 
      treatment with bleomycin and HUCMSCs conditioned medium (HUCMSCs-CM), 
      respectively, or together in vitro. In addition, we examined the secretome of 
      HUCMSCs in regular and inflammatory stimulation conditions. Our results 
      demonstrated that prophylactic HUCMSC administration before bleomycin-induced 
      modeling process could significantly meliorate damage to pulmonary fibrosis. 
      After the deletion of HIF-1alpha, damage markers in A549 cells were significantly 
      reduced in therapeutic administration condition. However, it was the opposite in 
      prophylactic administration condition. The results confirmed that HUCMSCs had 
      available preventive effect on bleomycin-induced pulmonary fibrosis in vivo and 
      in vitro. However, it may have a negative effect in therapeutic administration 
      condition because of the dual effect of HIF-1alpha.
CI  - Copyright (c) 2021 Hongpeng Zhang et al.
FAU - Zhang, Hongpeng
AU  - Zhang H
AD  - Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 2066 Wangyuan Road, Shanghai 
      201499, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 2066 Wangyuan Road, Shanghai 
      201499, China.
FAU - Xia, Yong
AU  - Xia Y
AD  - Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 2066 Wangyuan Road, Shanghai 
      201499, China.
FAU - Qi, Nianmin
AU  - Qi N
AUID- ORCID: 0000-0002-8580-0925
AD  - Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 2066 Wangyuan Road, Shanghai 
      201499, China.
LA  - eng
PT  - Journal Article
DEP - 20211126
PL  - United States
TA  - Stem Cells Int
JT  - Stem cells international
JID - 101535822
PMC - PMC8642016
COIS- The authors indicated no potential conflicts of interest.
EDAT- 2021/12/07 06:00
MHDA- 2021/12/07 06:01
PMCR- 2021/11/26
CRDT- 2021/12/06 09:09
PHST- 2020/12/25 00:00 [received]
PHST- 2021/11/01 00:00 [revised]
PHST- 2021/11/13 00:00 [accepted]
PHST- 2021/12/06 09:09 [entrez]
PHST- 2021/12/07 06:00 [pubmed]
PHST- 2021/12/07 06:01 [medline]
PHST- 2021/11/26 00:00 [pmc-release]
AID - 10.1155/2021/6658855 [doi]
PST - epublish
SO  - Stem Cells Int. 2021 Nov 26;2021:6658855. doi: 10.1155/2021/6658855. eCollection 
      2021.